[1] |
Warrell D, Gutiérrez JM. Rabies and envenomings: a neglected public health issue: report of a consultative meeting, 2007. |
[2] |
Yao HW, Yang Y, Liu K, et al. The spatiotemporal expansion of human rabies and its probable explanation in mainland China, 2004-2013. PLoS neglected tropical diseases, 2015; 9, e0003502. doi: 10.1371/journal.pntd.0003502 |
[3] |
World Health Organization. WHO Expert Committee on Rabies, Guide for post-exposure treatment, 8th report, WHO Technical Report Series, No. 824, Geneva Switzerland: World Health Organ. 1992. |
[4] |
Lang J, Simanjuntak GH, Soerjosembodo S, et al. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. Bull WHO, 1998; 76, 491-5. http://apps.who.int/iris/handle/10665/56026 |
[5] |
Chutivongse S, Wilde H, Fishbein DB, et al. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine, 1991; 9, 573-6. doi: 10.1016/0264-410X(91)90244-Z |
[6] |
Rupprecht CE, Briggs D, Brown CM, et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices: Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep, 2010; 59, 1-9. |
[7] |
Hua ZL, Gui HH, Qing T, et al. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Human Vaccines, 2011; 7, 220-4. doi: 10.4161/hv.7.2.14003 |
[8] |
Quan H, Man QL, Zheng GZ, et al. Comparison of safety and immunogenicity of purified chick embryo cell vaccine using Zagreb and Essen regimens in patients with category Ⅱ exposure in China. Hum Vaccin Immunother, 2014; 10, 1645-9. doi: 10.4161/hv.28420 |
[9] |
Colnot F, Sureau P, Alexandre JL, et al. Post-exposure antirabies vaccination, Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule. Presse Med, 1994; 23, 1609-12. http://d.scholar.cnki.net/detail/SJPD6079_U/SJPD12103102582157 |